Hemolytic Uremic Syndrome in Pregnancy and Postpartum
- PMID: 28596415
- PMCID: PMC5544502
- DOI: 10.2215/CJN.00280117
Hemolytic Uremic Syndrome in Pregnancy and Postpartum
Abstract
Background: Pregnancy is associated with various forms of thrombotic microangiopathy, including hemolytic uremic syndrome. A previous small French study suggested that pregnancy-associated hemolytic uremic syndrome was to be included in the spectrum of atypical hemolytic uremic syndrome linked to complement alternative pathway dysregulation.
Design, setting, participants, & measurements: We sought to retrospectively analyze the presentation, outcome, and frequency of complement alternative pathway gene variants in a larger international (France, United Kingdom, Italy) cohort of patients with pregnancy-associated hemolytic uremic syndrome.
Results: Eighty-seven patients with pregnancy-associated hemolytic uremic syndrome were included. Hemolytic uremic syndrome occurred mainly during the first pregnancy (58%) and in the postpartum period (76%). At diagnosis, 56 (71%) patients required dialysis. Fifty-six (78%) patients underwent plasma exchanges, 21 (41%) received plasma infusions, and four (5%) received eculizumab. During follow-up (mean duration of 7.2 years), 41 (53%) patients reached ESRD, 15 (19%) had CKD, and 18 (28%) patients experienced hemolytic uremic syndrome relapse. Twenty-four patients (27%) received a kidney transplant and a recurrence of hemolytic uremic syndrome occurred in 13 (54%) patients. Variants in complement genes were detected in 49 (56%) patients, mainly in the CFH (30%) and CFI genes (9%).
Conclusions: Pregnancy-associated hemolytic uremic syndrome and atypical hemolytic uremic syndrome nonrelated to pregnancy have the same severity at onset and during follow-up and the same frequency of complement gene variants.
Keywords: Antibodies, Monoclonal, Humanized; Atypical Hemolytic Uremic Syndrome; Complement Pathway, Alternative; Female; Follow-Up Studies; France; Humans; Italy; Kidney Failure, Chronic; Plasma Exchange; Postpartum Period; Pregnancy; Recurrence; Retrospective Studies; Thrombotic Microangiopathies; United Kingdom; chemotactic factor inactivator; complement; eculizumab; hemolytic uremic syndrome; kidney transplantation; pregnancy; renal dialysis; thrombotic microangiopathy.
Copyright © 2017 by the American Society of Nephrology.
Figures
References
-
- Noris M, Remuzzi G: Atypical hemolytic-uremic syndrome. N Engl J Med 361: 1676–1687, 2009 - PubMed
-
- Zuber J, Fakhouri F, Roumenina LT, Loirat C, Frémeaux-Bacchi V; French Study Group for aHUS/C3G : Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies. Nat Rev Nephrol 8: 643–657, 2012 - PubMed
-
- Frimat M, Decambron M, Lebas C, Moktefi A, Lemaitre L, Gnemmi V, Sautenet B, Glowacki F, Subtil D, Jourdain M, Rigouzzo A, Brocheriou I, Halimi JM, Rondeau E, Noel C, Provôt F, Hertig A: Renal cortical necrosis in postpartum hemorrhage: A case series. Am J Kidney Dis 68: 50–57, 2016 - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
